Express Pharma
Home  »  Management  »  Type II diabetes market in South-East Asia set to experience strong growth

Type II diabetes market in South-East Asia set to experience strong growth


According to GBI Research, the type II diabetes market will hit $2.9 billion by 2023

The South-East Asian Type II Diabetes Mellitus (T2DM) market, which includes South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, will rise from $1.92 billion in 2016 to $2.96 billion by 2023, at a compound annual growth rate (CARG) of 6.3 per cent, according to business intelligence provider GBI Research.

The company’s latest report ‘Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth’ reveals that there has been a steep rise in T2DM cases across the eight South-East Asian markets over the past decade. This can be attributed to a variety of factors, including changing lifestyle habits and aging populations. However, the drug treatment rate remains relatively low due to the asymptomatic nature of the disease, the availability of alternative treatment options such as traditional medicines and the recommendation of lifestyle modifications as the first-line therapy.

Gautam Arora, Healthcare Analyst, GBI Research, explains, “Unmet needs related to patient convenience and ease of use will be significantly addressed over the forecast period. Higher levels of innovation are apparent in the early – stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy over the long term.”

The late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes compared with currently marketed products. These are Novo Nordisk’s NN-9535 and OG-217SC, which are GLP-1 agonists; Pfizer’s ertugliflozin and Theracos’s bexagliflozin, which are SGLT-2 inhibitors; Sanofi’s sotagliflozin, which is dual SGLT-1 and SGLT-2 inhibitor and Merck’s omarigliptin, which is a DPP-4 inhibitor.

Of these products, GBI Research believes that OG-217SC, being a first-to-market oral formulation in the GLP-1 class of drug, has the most potential to change the treatment paradigm due to its improved administration route compared to other drugs in the same class.

In terms of recently approved therapeutics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors have already achieved strong market uptake and are all expected to increase their market share over the forecast period. In comparison with many previously marketed therapies, these new products provide improved weight control and lowered hypoglycemia risk.

Arora added, “In countries such as Thailand, Indonesia, and Vietnam, where affordability is a limiting factor, metformin – a low-cost generic drug – will maintain its pivotal role in the T2DM treatment algorithm. Due to its well-characterised safety and efficacy profiles, wide availability and low cost, metformin will continue to be prescribed as the first-line pharmacotherapy and also remain the favoured option for use in combination therapies.”

Comments are closed.